BRAF and Miyoshi myopathy: One such study illustrated the ability of FIS to potentiate the efficiency of the RAF inhibitor sorafenib to inhibit cell growth, block colony formation, and trigger apoptosis in three BRAF-mutated MM cells (i.e., A375, SK-MEL-28, and RPMI-7951) [48].